Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 4.67% at $181.16 after the company received FDA approval for Emergency Use Authorization for a second booster dose of its COVID-19 vaccine.

Benzinga

FDA Authorizes Fourth Dose Of Moderna, Pfizer/BioNTech COVID-19 Vaccines For Older People

The FDA has approved a second round of the Moderna Inc (NASDAQ:

Benzinga

FDA clears way for millions to get additional COVID-19 boosters

U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA approves another COVID booster for 50 and up

The Food and Drug Administration’s decision opens a fourth dose of the Pfizer or Moderna vaccines to those people at least four months after their previous booster.

Chicago Sun-Times

FDA approves another Pfizer, Moderna Covid booster for 50 and up

US regulators are allowing people 50 and older to get another booster dose of the Pfizer or Moderna Covid-19 vaccine

The Independent UK

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

COVID-19 boosters, BA.2 subvariant, treatments: 6 things we still need to keep an eye on

Coronavirus case numbers have plummeted across much of the U.S., including Texas, a promising sign that COVID-19 could finally be waning. But the pandemic is far from over, especially for older adults, people with disabilities and other vulnerable populations.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

Covid vaccinations in US fall to lowest level since 2020

Public health experts say the low number of Americans receiving booster shots is an ‘unforgivable liability’

The Independent UK

What 10 Analyst Ratings Have To Say About Moderna

Within the last quarter, Moderna (NASDAQ:MRNA) has observed the following analyst ratings:

Benzinga

FDA advisory panel to discuss Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

The Independent UK

This Is What Whales Are Betting On Moderna

Benzinga

FDA advisory panel to discuss additional Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

The Independent UK

Moderna Says Infant Covid Vaccine Succeeded in Trial

US biotech firm Moderna on Wednesday said it was pursuing regulatory approval for its Covid vaccine in children under six years old after the two-shot regimen was found to be safe and produced a strong immune response. Specifically, two doses of 25 micrograms given to babies, toddlers and preschoolers generated…

Asharq Al-Awsat

Two-month-old baby's death in Newcastle confirmed to be from COVID-19

The NSW coroner has confirmed a two-month-old baby died of COVID-19 in December. The child is believed to be Australia's youngest COVID victim.

ABC News

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

EXPLAINER: What to know about COVID vaccines for little kids

Moderna says it will ask regulators to authorize its COVID-19 vaccine for children under 6 but several hurdles need to be cleared before the shots could become available

AAP

Australia secures Moderna vaccine facility

Hundreds of millions of mRNA vaccines will be made in Australia as part of a multi-billion dollar agreement with pharmaceutical giant Moderna.

Benzinga

Moderna's COVID-19 Vaccine Shows Neutralizing Antibody Response In Kids Under 6

Moderna Inc (NASDAQ:MRNA) has announced interim data from the Phase 2/3 KidCOVE study of its COVID-19 vaccine (mRNA-1273) in children six months to under six years. The interim analysis showed that two 25 μg doses of mRNA-1273 in participants 6 months to under six years met the primary endpoint with robust neutralizing antibody…

Tribune News Service

Moderna to seek emergency authorization for COVID-19 vaccine use for kids under 6

Kids, prep those arms.

Get all your
news in one place.

100’s of premium titles.
One news app.

ABC News

Moderna will produce its mRNA vaccines in Australia from 2024, with final deal signed off

The plant will have the capacity to produce up to 100 million vaccine doses each year, for COVID-19 and for other diseases like the seasonal flu.

Axios

Moderna says vaccine for kids under 6 generates strong immune response

"This interim analysis showed a robust neutralizing antibody response in both age groups."

The Independent UK

Moderna says its low-dose COVID shots work for kids under 6

Moderna says its COVID-19 vaccine works in babies, toddlers and preschoolers

The Independent UK

FDA advisory panel to discuss additional Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

Benzinga

Why Moderna Shares Are Trading Higher Today

Moderna Inc (NASDAQ: MRNA) shares are trading higher Tuesday after the company announced two new vaccine candidate developments.

Benzinga

Moderna Bolsters Its Pipeline With Two New mRNA-Based Vaccine Programs

Moderna Inc (NASDAQ:MRNA) expands its mRNA pipeline with two new development programs ahead of Annual Vaccines Day, building on Moderna's experience with Spikevax, its COVID-19 vaccine. The development programs include a combination respiratory vaccine candidate and a new program against all four endemic human coronaviruses (HCoV). First, Moderna is launching a respiratory combination…

The Independent UK

No funds to buy fourth Covid vaccine dose for all Americans, White House warns

Funding for coronavirus aid stalled in Congress leaving vaccine and therapeutics purchases lacking

1 … 26 27 28 29

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

European Medicines Agency

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.